TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
Brief Summary: This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:


Options:
A: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis: PATIENT-UC
Brief Summary: Hospitalized patients with ulcerative colitis (UC) are at increased risk for a variety of complications such as infections, venous thrombosis, and surgery. The literature has revealed significant variation in the quality of care to hospitalized UC patients. As a result, guidelines for the management of these patients have been developed. However, the update of guidelines are variable. Admission to hospital can also have significant impact on quality of life due to interruptions in life commitments and lost sense of control of disease. Maintaining a sense of self-control of disease and active participation in care has been shown to be valuable among individuals with chronic diseases. The investigators propose the development of a multi-site, patient centred initiative aimed at improving clinical and patient-centered outcomes through an educational iPad based tool for patients admitted to hospital with ulcerative colitis.


Options:
A: Arm Label: Educational Video; Type: EXPERIMENTAL; Interventions: Other: Educational video | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational video; Assigned to Arm(s): Educational Video
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Weekly Home Monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Arm Label: Home Monitoring Every Other Week; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Weekly Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring Every Other Week
C: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Arm Label: Group 1 (IBD Nurse CONSULT + BOOKLET); Type: EXPERIMENTAL; Interventions: Other: IBD nurse intervention | Arm Label: Group 2 (BOOKLET alone); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: IBD nurse intervention; Assigned to Arm(s): Group 1 (IBD Nurse CONSULT + BOOKLET)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recruiting to Clinical Trials on the Telephone
Brief Summary: This study examined the use of the telephone for the purpose of informing expectant mothers about a randomized clinical trial assessing neonatal Bacille Calmette-Guérin vaccination. Expectant mothers who were contacted for participation in a vaccination trial (the Calmette study, NCT01694108) were randomized to receive information by telephone or at a face-to-face consultation. The primary outcome was a communication score, consisting of comprehension of information about the study and satisfaction with the information process. The outcome was measured using a questionnaire two weeks after the information was provided and two and a half months after birth.


Options:
A: Arm Label: telephone; Type: EXPERIMENTAL; Interventions: Behavioral: telephone | Arm Label: face-to-face; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: consultation face-to-face | Intervention Type: BEHAVIORAL; Name: telephone; Assigned to Arm(s): telephone | Intervention Type: BEHAVIORAL; Name: consultation face-to-face; Assigned to Arm(s): face-to-face
B: Intervention Type: DRUG; Name: VRC-FLUDNA047-00-VP; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Flulaval (Registered) Seasonal Influenza Vaccine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: Celecoxib; Type: EXPERIMENTAL; Interventions: Drug: Celecoxib | Arm Label: Diclofenac; Type: ACTIVE_COMPARATOR; Interventions: Drug: Diclofenac | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): Celecoxib | Intervention Type: DRUG; Name: Diclofenac; Assigned to Arm(s): Diclofenac

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP (Nasal Continuous Positive Airway Pressure) in Preterm Infants With Mild to Moderate Respiratory Distress Syndrome (RDS): a Randomized Clinical Trial.
Brief Summary: Preterm infants ranging from 29+0 to 36+6 weeks+days are randomly assigned to one of the following treatments as non invasive respiratory support if they develop mild to moderate Respiratory Distress Syndrome within 72 hrs from birth: 1) NCPAP set at 4-6 cmH2O or 2) HHHFNC providing a flow 4-6 l/min.

The aim of the study is to assess efficacy and safety of relative "new" form of respiratory support (HHHFNC) versus a more common one (NCPAP).


Options:
A: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A
B: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
C: Arm Label: HHHFNC; Type: EXPERIMENTAL; Interventions: Device: HHHFNC | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP
D: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Clinical Effectiveness of Freezing All Embryos Followed by Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer, in Women Undergoing In-vitro Fertilization Treatment
Brief Summary: The objective of the present randomized controlled study is to compare clinical effectiveness and safety of freezing all embryos followed by frozen-thawed embryo transfer (FET) compared to fresh embryo transfer, in women undergoing IVF treatment.


Options:
A: Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh embryo transfer | Arm Label: Intervention arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Frozen embryo transfer | Intervention Type: PROCEDURE; Name: Fresh embryo transfer; Assigned to Arm(s): Control arm | Intervention Type: PROCEDURE; Name: Frozen embryo transfer; Assigned to Arm(s): Intervention arm
B: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol
C: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
D: Arm Label: Day 3 eSET combined with Eeva; Type: ACTIVE_COMPARATOR; Interventions: Device: Eeva™ results | Arm Label: Day 5 eSET combined with Eeva; Type: ACTIVE_COMPARATOR; Interventions: Device: Eeva™ results | Arm Label: Day 5 eSET with Traditonal Morphology; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Eeva™ results; Assigned to Arm(s): Day 3 eSET combined with Eeva, Day 5 eSET combined with Eeva

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings
Brief Summary: Using a single-arm trial design, this study will examine the feasibility and acceptability of evaluating QuitAdvisorDDS, a clinical decision support software application designed to facilitate implementation of evidence-based tobacco treatment interventions into the dental setting. The study will examine the feasibility and acceptability of evaluating the impact of the QuitAdvisorDDS tool on patient outcomes related to tobacco use and cessation attempts as well as provider knowledge, attitudes, and practices regarding tobacco treatment. Practitioners (dentists and hygienists) will complete surveys at baseline and follow-up, while patients will complete surveys at baseline and 1-month follow-up. An embedded substudy will also evaluate the feasibility and acceptability of collecting biospecimens (saliva) to serve as biochemical verification of smoking status.


Options:
A: Arm Label: QA-DDS; Type: EXPERIMENTAL; Interventions: Behavioral: QA-DDS | Intervention Type: BEHAVIORAL; Name: QA-DDS; Assigned to Arm(s): QA-DDS
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of the Effects of Mindfulness on Impulsive Eating, Motivation Toward Exercise, and Weight Loss in Obese Patients: Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the efficacy of a daily 12-month computerized mindfulness-based intervention in obese patients diagnosed with Binge Eating Disorder (BED) on: impulsive eating, motivation toward exercise, and weight loss.


Options:
A: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based intervention | Arm Label: Sham meditation; Type: SHAM_COMPARATOR; Interventions: Behavioral: Sham meditation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based intervention; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: Sham meditation; Assigned to Arm(s): Sham meditation
B: Arm Label: Standard group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard | Arm Label: Mind&Life (standard + intervention) group; Type: EXPERIMENTAL; Interventions: Behavioral: Mind&Life, Behavioral: Standard | Intervention Type: BEHAVIORAL; Name: Mind&Life; Assigned to Arm(s): Mind&Life (standard + intervention) group | Intervention Type: BEHAVIORAL; Name: Standard; Assigned to Arm(s): Mind&Life (standard + intervention) group, Standard group
C: Arm Label: Stress reduction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction | Arm Label: Stress reduction with Health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress reduction with Health education | Intervention Type: BEHAVIORAL; Name: Stress reduction; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Stress reduction with Health education; Assigned to Arm(s): Stress reduction with Health education
D: Arm Label: Face-to-Face; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Mobile; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (Internet) | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: No intervention | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (ACT); Assigned to Arm(s): Face-to-Face, Mobile | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (Internet); Assigned to Arm(s): Internet | Intervention Type: BEHAVIORAL; Name: No intervention; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Brief Summary: This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.


Options:
A: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo
B: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care
C: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
D: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Brief Summary: This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.


Options:
A: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Other: Blood and derivatives. | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care | Intervention Type: OTHER; Name: Blood and derivatives.; Assigned to Arm(s): Treatment Arm | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Control Arm
B: Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine care for COVID-19 patients | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2 | Intervention Type: OTHER; Name: plasma therapy using convalescent plasma with antibody against SARS-CoV-2; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Routine care for COVID-19 patients; Assigned to Arm(s): Control group
C: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: INM005 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INM005; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Brief Summary: This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.


Options:
A: Intervention Type: BIOLOGICAL; Name: COVID-19 convalescent plasma; Assigned to Arm(s): N/A
B: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
C: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care
D: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo

Answer: B